Complementary cancer care using Ayurveda and integrative approaches : An observational study

Recruiting

• Conditions: Neoplasms. Ayurveda Condition: ARBUDAH,

• Registration Number: CTRI/2023/07/055657
• Lead Sponsor: RISt- Rural India Supporting Trust

Brief Summary

Background In India, cancer accounts for 9% of all deaths and the number of cases reported for the year 2020 was 1,392,179. From the recent 2022 reports of ICMR-NCDIR-NCRP data, it is observed that there is a steep 2-fold rise in the cancer burden in India with a projected alarming rise by 12% between 2020 – 2025.

There is a need for Observational and real world data on the utility of Ayurveda in cancer care alongside deeper mechanistic studies

AIM: Systematic documentation and evaluation of outcomes of cancer patients volunteering at an Ayurveda hospital   OBJECTIVES: •    Measuring quality of life changes in cancer patients using globally accepted tools of measurement. •    Measuring progression rate of solid tumours •    Analysing Health seeking behaviour of Cancer patients. •    To evaluate the outcomes of cancer management at I-AIM through retrospective data analysis

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-08
• Last Update Posted: 2024-01-31

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

All cancer patients visiting Rasayana tantra unit at I-AIM.

Exclusion Criteria

Patients unable to provide data due to any reasons (like giving additional time for data collection or due to altered mental status).

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
•Quality of life measurements using EORTC-QLQ-c30, ECOG, VAS	1 year
•Patient-reported outcomes	1 year

Secondary Outcome Measures

Name	Time	Method
•Conduct basic blood biochemistry (Hb%, CBC, LFT, RFT, FBS, PPBS, HbA1c, urine routine) to ensure the safety of Ayurveda interventions along with inflammatory markers like CRP, D-dimer & albumin.	•Disease-specific cancer markers and RECIST 1.1 to assess progression wherever necessary

Trial Locations

Locations (1)

Institute of Ayurveda and Integrative Medicine; 🇮🇳 Bangalore, KARNATAKA, India

Institute of Ayurveda and Integrative Medicine

🇮🇳Bangalore, KARNATAKA, India

DrPrasan Shankar

Principal investigator

9945426118

prasan.shankar@iaimhealthcare.org